Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997373 · ClinicalTrials.gov registry record · NA
Letrozole as a Treatment of Endometrial Cancer
A NA study, sponsored by University of California, Davis.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
NCT00997373 is a NA study that has completed, run by University of California, Davis. The registered enrollment target is 43 participants.
The verdict
NCT00997373, a NA study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
Study Summary
Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the estrogen receptor molecule that exist within the cancer tissues. To participate in this study, the patients must be 40 years of age or older and have biopsy-proven endometrial carcinoma, either well differentiated or moderately differentiated forms. Also, to be eligible to participate in this study, the patients need to be healthy enough to have a hysterectomy. If the patients are less than age 60, they will need a blood test (FSH) to confirm that they have gone into menopause.
Interventions
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-10 |
| Est. Completion | 2013-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997373
The ClinicalTrials.gov registry entry for NCT00997373 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Letrozole is the first listed.
NCT00997373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00997373 about?
NCT00997373 is a clinical study titled "Letrozole as a Treatment of Endometrial Cancer". Some cases of endometrial cancer are dependent on estrogen for their growth. Letrozole blocks estrogen production in the body. The purpose of this study is to determine if the investigators can predict which patients might benefit from Letrozole treatment by studying the many different forms of the ...
What is the current status of trial NCT00997373?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2009-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00997373?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT00997373?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.